EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology
Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer
Rakha, Emad; Soria, Daniele; Green, Andrew R.; Lemetre, Christophe; Powe, Desmond G.; Nolan, Christopher C.; Garibaldi, Jonathan M.; Ball, Graham; Ellis, Ian O.
Authors
Daniele Soria
Andrew R. Green
Christophe Lemetre
Desmond G. Powe
Christopher C. Nolan
Jonathan M. Garibaldi
Graham Ball
Ian O. Ellis
Abstract
Current management of breast cancer (BC) relies on risk stratification based on well-defined clinicopathologic factors. Global gene expression profiling studies have demonstrated that BC comprises distinct molecular classes with clinical relevance. In this study, we hypothesized that molecular features of BC are a key driver of tumour behaviour and when coupled with a novel and bespoke application of established clinicopathologic prognostic variables, can predict both clinical outcome and relevant therapeutic options more accurately than existing methods. In the current study, a comprehensive panel of biomarkers with relevance to BC was applied to a large and well-characterised series of BC, using immunohistochemistry and different multivariate clustering techniques, to identify the key molecular classes. Subsequently, each class was further stratified using a set of well-defined prognostic clinicopathologic variables. These variables were combined in formulae to prognostically stratify different molecular classes, collectively known as the Nottingham Prognostic Index Plus (NPI+). NPI+ was then used to predict outcome in the different molecular classes with.Seven core molecular classes were identified using a selective panel of 10 biomarkers. Incorporation of clinicopathologic variables in a second stage analysis resulted in identification of distinct prognostic groups within each molecular class (NPI+). Outcome analysis showed that using the bespoke NPI formulae for each biological breast cancer class provides improved patient outcome stratification superior to the traditional NPI. This study provides proof-of-principle evidence for the use of NPI+ in supporting improved individualised clinical decision making.
Citation
Rakha, E., Soria, D., Green, A. R., Lemetre, C., Powe, D. G., Nolan, C. C., …Ellis, I. O. (2014). Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. British Journal of Cancer, 110(7), https://doi.org/10.1038/bjc.2014.120
Journal Article Type | Article |
---|---|
Publication Date | Mar 11, 2014 |
Deposit Date | Jan 30, 2015 |
Publicly Available Date | Jan 30, 2015 |
Journal | British Journal of Cancer |
Print ISSN | 0007-0920 |
Electronic ISSN | 1532-1827 |
Publisher | Cancer Research UK |
Peer Reviewed | Peer Reviewed |
Volume | 110 |
Issue | 7 |
DOI | https://doi.org/10.1038/bjc.2014.120 |
Public URL | https://nottingham-repository.worktribe.com/output/725340 |
Publisher URL | http://www.nature.com/bjc/journal/v110/n7/full/bjc2014120a.html |
Files
Rakha2014.pdf
(1.1 Mb)
PDF
You might also like
Cell Division Cycle 6 (CDC6) is an Independent Prognostic Biomarker in Breast Cancer
(2024)
Journal Article
The role of the ALKBH5 RNA demethylase in invasive breast cancer
(2024)
Journal Article
Stromal lymphocytes are associated with upgrade of B3 breast lesions
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search